A 12-week double-blind randomized clinical trial of vitamin Dsupplementation on body fat mass in healthy overweight and obese women by unknown
Salehpour et al. Nutrition Journal 2012, 11:78
http://www.nutritionj.com/content/11/1/78RESEARCH Open AccessA 12-week double-blind randomized clinical trial
of vitamin D3 supplementation on body fat mass
in healthy overweight and obese women
Amin Salehpour1, Farhad Hosseinpanah2*, Farzad Shidfar1, Mohammadreza Vafa1, Maryam Razaghi1,
Sahar Dehghani1, Anahita Hoshiarrad3 and Mahmoodreza Gohari4Abstract
Background: Vitamin D concentrations are linked to body composition indices, particularly body fat mass.
Relationships between hypovitaminosis D and obesity, described by both BMI and waist circumference, have been
mentioned. We have investigated the effect of a 12-week vitamin D3 supplementation on anthropometric indices
in healthy overweight and obese women.
Methods: In a double-blind, randomized, placebo-controlled, parallel-group trial, seventy-seven participants
(age 38±8.1 years, BMI 29.8±4.1 kg/m2) were randomly allocated into two groups: vitamin D (25 μg per day as
cholecalciferol) and placebo (25 μg per day as lactose) for 12 weeks. Body weight, height, waist, hip, fat mass,
25(OH) D, iPTH, and dietary intakes were measured before and after the intervention.
Results: Serum 25(OH)D significantly increased in the vitamin D group compared to the placebo group
(38.2±32.7 nmol/L vs. 4.6±14.8 nmol/L; P<0.001) and serum iPTH concentrations were decreased by vitamin D3
supplementation (-0.26±0.57 pmol/L vs. 0.27±0.56 pmol/L; P<0.001). Supplementation with vitamin D3 caused a
statistically significant decrease in body fat mass in the vitamin D group compared to the placebo group
(-2.7±2.1 kg vs. -0.47±2.1 kg; P<0.001). However, body weight and waist circumference did not change significantly
in both groups. A significant reverse correlation between changes in serum 25(OH) D concentrations and body fat
mass was observed (r = -0.319, P = 0.005).
Conclusion: Among healthy overweight and obese women, increasing 25(OH) D concentrations by vitamin D3
supplementation led to body fat mass reduction.
This trial is registered at clinicaltrials.gov as NCT01344161.
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Obesity is a chronic condition of nutrients accumulation
[1,2] in which excess energy aggregates in the form of fat
mass [3]. Based on the thrifty genotype hypothesis [4],
since metabolic efficiency is raised in negative energy
states, important interactions between gene and obeso-
genic environment (including food abundance and low
physical activity [5]) result in improper metabolic* Correspondence: fhospanah@endocrine.ac.ir
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reproduction in any medium, provided the orprogramming and epigenic change in utero; hence in this
condition obesity is an inevitable outcome [6]. Fat mass
distribution specifically visceral distribution, produces
toxic milieu by initiating metabolic and inflammatory cas-
cade, which is followed by endocrine, cardiovascular and
malignant events. The risk of mortality rises synergistically
with increase in BMI over than 30 kg/m2 [1].
Serum 25-hydroxyvitamin D concentrations are low in
obese adults [7,8] and linked to components of body
composition, particularly body fat mass [9,10]. Altera-
tions in the vitamin D endocrine system have been
reported in obesity [11,12]. Lumb et al believed that vita-
min D is stored in adipose and muscle tissues afterral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[13,14]. It was thought that vitamin D deficiency caused
obesity, and is proposed that hypothalamus diagnoses
low calcidiol concentrations in circulation and induces
higher body set point by increase in appetite and
decrease in energy consumption via stimulating Agouti
Related Protein/Neuropeptide Y (AgRP/NPY) and sup-
pressing pro-Opiomelanocortin/Cocaine- Amphetamine-
Regulated Transcription (POMC/CART) pathway [15,16].
Wortsman et al confirmed insufficiency of vitamin D in
the obese people indicating that they need to higher doses
of vitamin D [17].
Evidence implies that dairy product consumption, and
high calcium and/or vitamin D intakes can repress fatty
acid synthase enzyme (FAS) by decreasing intracellular
Ca + 2 in adiposities [18-21]. Recent literature reveals
that vitamin D receptor (VDR) gene polymorphisms are
associated with adiposity phenotypes [22]. It has been
postulated that both 1,25(OH)2D and VDR have impera-
tive roles in adipocyte differentiation [23,24]. The differ-
entiation of pre-adipocytes to mature adipocytes in vitro
is halted by 1,25(OH)2D3 [24]. Contrarily, high serum
1,25(OH)2 D concentrations may increase lipogenesis by
stimulating of FAS [25].
Alterations in the vitamin D endocrine system are caus-
ally associated with augmented adiposity or result from
augmented fat mass storage of vitamin D [17]. Accumula-
ting evidence for involvement of vitamin D in fat mass
metabolism [25] was the impetus for this clinical trial in
which we tested the effect of vitamin D3 supplementation
on body composition in overweight and obese women.
Methods
Subjects
We conducted the study between November 2009 and
April 2010 in the Heart and Vascular Laboratory in
Pharmacology Department of Tehran University of Me-
dical Sciences, Tehran, Iran. Recruitment began in August
2009 by advertisements on university and ended in
November 2009. The criteria for eligibility were age be-
tween 18-50 years old, a BMI ≥25 kg/m2, an apparently
healthy status based on self-reports from the subjects, free
from metabolic bone disease, gastrointestinal disease, dia-
betes mellitus, cardiovascular disease, renal disease, no
medications, no vitamin supplements, none pregnant or
lactating. We excluded individuals with changes in body
weight more than 3 kg within last three months, following
weight-loss programs, taking weight loss drugs, smoking
and drinking alcohol. Of a total of 140 subjects initially
selected, eighty five subjects who met the above inclusion
criteria were recruited.
The present study was approved by the Ethics Committee
of the Tehran University of Medical Sciences and
Iranian Registry of Clinical Trial (registration no.IRCT138809092709N2) and written informed consent
and subject assent were obtained.
Design
Individuals were randomly allocated in a double-blind
parallel manner from randomized number in an 85-
person list; 42 women were assigned to the vitamin D
group and 43 women to the placebo group. The vitamin
D group had to take vitamin D3 supplement tablet
of 25 μg/d as cholecalciferol; Merck Pharma GmbH,
Germany, while the placebo group took tablet of 25 μg/d
as lactose; Merck Pharma GmbH, Germany. The inter-
vention was conducted for 90 days. To ensure and assess
compliance, vitamin D supplements were issued at base-
line, exchanged for a new package at both 4 wk and 8
wk, and returned to the research staff at post testing,
and pills were counted later for compliance, which was
87.1% in the vitamin D and 87.4% in the placebo groups.
To remain blinded, one research assistant who was not
involved in data collection coordinated the supplement
assignment schedule.
In a per-protocol analysis, eight subjects were excluded
during the intervention (Figure 1); in the placebo group,
four subjects were unwilling to continue the 12-week
intervention for personal reasons and another subject used
oral contraceptive pills. In the vitamin D group, one sub-
ject followed a weight reduction program, one got preg-
nant and one was unwilling to continue the 12-week
intervention for personal reasons. Eventually 77 subjects
completed the study, 39 in the vitamin D group and 38 in
the placebo group.
After a 12-h overnight fast, blood specimens were col-
lected from the antecubital vein into the tubes. After
centrifugation for 20 min (3000 g), the serum samples
were frozen consecutively and stored at -80°C.
We assessed energy and nutrient intakes by 24 h food
recall and validated food frequency questionnaires [26].
A nutritionist completed questionnaires during monthly
face to face interviews. Because the Iranian food com-
position table (FCT) is incomplete (limited to only raw
materials and few nutrients) [27], each food and beve-
rage was analyzed for nutrient intake using Nutritionist
IV software (Version 4.1, First Databank Division, The
Hearst Corporation, San Bruno, CA) to assess macronu-
trient and micronutrient contents of foods. The Iranian
FCT was used as an alternative for traditional Iranian
food items, such as kashk, which are not included in the
Food Composition Tables for USA (USDA FCT) [28].
The average of MET-minutes/week was calculated by
multiplying the time of exercise by the respective meta-
bolic equivalent task (MET) using the International
Physical Activity Questionnaires (IPAQ) [29].
We measured body weight to the nearest 0.1 kg and
height in light indoor clothes using a digital scale (model
Assessed for eligibility (n=140)
Medical examination (n=85)
Excluded (n=55)
Did not meet inclusion criteria
Randomized (n=85)
Assigned to placebo group (n=43)Assigned to vitamin D group (n=42)
Lost to follow up (n=5)
Non compliant (n=4)
Take OCP (n=1)
Lost to follow up (n=3)
Non compliant (n=1)
Pregnancy (n=1)
follow weight reduction program (n=1)
Completed 12-week follow-up (n=39) Completed 12-week follow-up (n=38)
Analyses (n=39) Analyses (n=38)
Figure 1 Follow of participants throughout the intervention.
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and hip circumference were measured on a horizontal
plane at the level of the iliac crest by an Ergonomic
Circumference Measuring Tape (model 201; Seca GmbH
& Co, KG, Hamburg, Germany). Body mass index was cal-
culated as weight in kilograms divided by the square of
the height in meters. We assessed body fat mass and fat
free mass by Bioelectrical Impedance Analysis (model
4000; Body Stat Quad Scan, Douglas Isle of Man, British
Isles) after five minutes resting, with standard errors of es-
timate (accuracy) of 4.1%. All anthropometric indices were
obtained using the WHO standard procedures [30].
Biochemical measurements
Intact PTH was measured by immunoenzymo-metric
assay (IEMA) (Immunodiagnostic Systems Ltd, Boldon,
UK). Intra- and interassay CVs for intact PTH were 5.5%,
and 8.3%, respectively. Serum 25(OH) D was measured by
enzyme immunoassay (EIA) (Immunodiagnostic Systems
Ltd, Boldon, UK). Intra- and interassay CVs for 25(OH) D
were 6.9%, and 8.1%, respectively. Calcium was measured
by colorimetric enzymatic (Pars Azmoon, Tehran, Iran),the kit expected range was 2.15-2.57 mmol/L. The assay
sensitivity was 0.05 mmol/L, and intra- and interassay
coefficients of variation were 2.4% and 3%, respectively.
Phosphorus was measured by enzymatic photometric UV
test (Pars Azmoon Co., Tehran, Iran); the kit expected
range was 0.83-1.45 mmol/L. The assay sensitivity was
0.22 mmol/L, and intra- and interassay coefficients of va-
riation were 3.2% and 4.1%, respectively.
Statistical analysis
Descriptive statistics are presented as mean ± SD. We
examined the normality of data by Kolmogorov-Smirnov
and Shapiro-Wilk tests. All data had been normally dis-
tributed. For the primary analysis, we used an analysis of
covariance (ANCOVA) to adjust mean differences on
biochemical variables. Simple Pearson correlations were
computed between changes in 25(OH) D and iPTH con-
centrations and body fat mass. All statistical analyses
were performed using SPSS (version 16; SPSS Inc,
Chicago, IL). All tests were two-sided and P values <0.05
were considered statistically significant.
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Participant characteristics are given in Table 1. Baseline
characteristics were similar in the vitamin D and pla-
cebo groups (Table 1). Serum 25(OH) D concentrations
increased to (75 ± 22 nmol/L vs. 51.5 ± 31 nmol/L;
P<0.001), respectively in the vitamin D group, in com-
parison to the placebo group after 12 weeks (Table 2).
Although serum iPTH concentrations decreased in the
vitamin D group, these concentrations increased in the
placebo group (-0.26 ± 0.5 pmol/L vs. 0.27 ± 0.5 pmol/L;
P<0.001), respectively. In the vitamin D group, weight
loss was (-0.3 ± 1.5 kg) whereas in the placebo group, it
was (-0.1 ± 1.7 kg), differences were not statistically sig-
nificant between the two groups. Waist circumference
decreased in the vitamin D group, but increased in the
placebo group (-0.3 ± 4.3 cm vs. 0.4 ± 4.1 cm), respectively.
Hip circumference decreased (-0.39 ± 2.4 cm in the vita-
min D group and -0.9 ± 2.4 cm in the placebo group), dif-
ferences were not statistically significant between the two
groups. Body fat mass decreased in the vitamin D and pla-
cebo groups (-2.7 ± 2 kg and -0.4 ± 2 kg; P<0.001). There
were significant inverse correlations between changes in
serum 25(OH) D concentrations and body fat mass
(r = -0.319, P = 0.005) (Figure 2), and iPTH concentrations
(r = -0.318, P = 0.005). A significant positive and correl-
ation was observed between changes in serum iPTHTable 1 Baseline characteristics of subject groups who receive
the intervention
Characteristics Vitamin D grou
Age (y) 38±72
Body weight (kg) 73.9±10.2
Height (cm) 156.5±5.8
Waist circumference (cm) 89.9±8.7
Hip circumference (cm) 108±8.5
BMI (kg/m2) 30.1±3.9
Fat mass (kg) 30.2±6.9
Fat free mass (kg) 43.7±5.1
Physical activity (MET-minutes/week) 902±1245
Energy intake (kcal/d) 1866±927
Carbohydrate intake (g/d) 280±134
Fiber intake (g/d) 16±9
Protein intake (g/d) 64±29
Fat intake (g/d) 55±44
Dietary calcium intake (mg/d) 873±586
Dietary vitamin D intake (μg/d) 0.53±0.6




aMean ± SD (all such values).
b25(OH) D, 25-hydroxyvitamin D; PTH, parathyroid hormone. To convert 25(OH) D vconcentrations and body fat mass (r = 0.32, P = 0.004)
(Figure 3), while there were no significant correlations be-
tween serum 25(OH)D concentrations and body fat mass
or iPTH concentrations.
Discussion
The present study shows that a 12 week supplementa-
tion with 25 μg vitamin D3 in overweight and obese
women with mean serum 25(OH)D concentrations of
41.8±31.4 nmol/L decreases body fat mass, but does not
affect body weight and waist circumference.
There is a large body of growing evidence showing
that dairy products, and calcium and vitamin D intake
play a role in the regulation of body fat mass [31-33].
Data also indicates that vitamin D may increase lean
body mass [34] and inhibit the development of adipo-
cytes. These effects of vitamin D may be mediated by
1,25(OH)2D3 or via suppression of PTH [35].
However, there are few clinical trials of vitamin D sup-
plementation on body composition and most of them
have assessed effects of combined calcium and vitamin
D supplementation. Moreover, these studies are hetero-
geneous with regard to doses and types of vitamin D,
lengths of follow up, outcome ascertainment methods,
prevalence of vitamin D deficiency and other character-
istics in studied subjects, which have led to inconsistentd vitamin D3 supplements (25 μ/d) or placebo before





















alues to ng/mL, divide by 2.5. To convert PTH values to pg/mL, divide by 0.11.
Table 2 Anthropometric, dietary and serum variables in the subject groups after vitamin D3 supplementation
and changes in variables between measurement periods
Characteristics Vitamin D group Placebo group P-valuea
Week 12 Changeb Week 12 Change
Body weight (kg) 73.5±10.43 -0.3±1.5 75±12.3 -0.1±1.7 0.71
Waist circumference (cm) 89.5±8.8 -0.3±4.3 91.6±13 0.4±4.1 0.38
Hip circumference (cm) 107.6±7.9 -0.39±2.4 107.3±7.2 -0.9±2.4 0.36
BMI (kg/m2) 30±4 -0.13±0.6 29.5±4.6 -0.04±0.6 0.50
Fat mass(kg) 28.2±7.5 -2.7±2.1 28.6±8.9 -0.47±2.1 <0.001
Fat free mass (kg) 45.5±4.9 1.8±2.1 46.2±5 0.4±2.1 <0.001
Physical activity (METminutes/week) 892±1488 -10±1627 1081±1372 379±1137 0.23
Energy intake (kcal/d) 2010±1289 143.7±1358.4 1852±992 -208±920.9 0.32
Carbohydrate intake (g/d) 312±186 31.8±194.6 294±164 -34.3±143 0.23
Fiber intake (g/d) 16±12 1±11.7 14±7 -4.3±11.3 0.10
Protein intake (g/d) 72±53 7.8±54.3 66±32 -9.3±35.6 0.29
Fat intake (g/d) 53±43 -2.3±52.2 45±36 -4.2±39.3 0.48
Dietary calcium intake (mg/d) 829±533 -43.9±674.4 625±454 -51.8±509.5 0.18
Dietary vitamin D intake (μg/d) 0.4±0.47 -0.09±0.77 0.37±0.35 -0.04±0.52 0.70
25(OH) D (nmol/L) 75±22 38.2±32 51.5±31 4.6±14 <0.001
PTH (pmol/L) 1.2±0.5 -0.2±0.5 1.7±0.8 0.2±0.5 <0.001
Calcium (mmol/L) 2.2±0.1 -0.02±0.1 2.3±0.09 -0.02±0.1 0.81
Phosphorus (mmol/L) 0.9±0.09 -0.12±0.1 1±0.09 -0.09±0.1 0.21
aAn analysis of covariance (ANCOVA) was used to adjust mean differences on all dependent variables.
bAfter 12 weeks.
Mean ± SD (all such values).
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have investigated the effect of vitamin D3 supplementa-
tion in overweight or obese women with low 25(OH)D
concentrations on body compositions. The 12 week vita-
min D3 supplementation did not significantly affect bodyFigure 2 Relation between alterations of serum 25(OH) D
concentrations and body fat mass.weight, waist or hip circumference. However, a modest fat
mass reduction of 7% was associated with a significant in-
crease of 25OHD levels by 103% and a significant decrease
of PTH levels by 14%. The initial serum 25(OH)D concen-
trations were low in both groups.
Recently, in a double-blind, placebo-controlled trial in
overweight and obese participants, Rosenblum et al [32]Figure 3 Relation between alterations of serum iPTH
concentrations and body fat mass.
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supplementation with either regular or reduced energy
(lite) orange juice (three 240 mL glasses of orange juice
fortified with 350 mg Ca and 100 IU vitamin D per ser-
ving), the average weight loss did not differ significantly
between groups, but in the regular orange juice trial, the
reduction of visceral adipose tissue (VAT) was significantly
greater in the CaD group than in controls (−12.7 ±
25.0 cm2 vs. −1.3 ± 13.6 cm2; P = 0.024, respectively) and
in the lite orange juice trial, the reduction of VAT was sig-
nificantly greater in the CaD group than in controls
(−13.1 ± 18.4 cm2 vs. − 6.4 ± 17.5 cm2; P = 0.039, respect-
ively) after control for baseline VAT. They suggested that
calcium and vitamin D supplementation contributes to a
beneficial reduction of VAT. Dong et al [36] in a 16 week
randomized, blinded, controlled clinical trial of 2000 IU
vitamin D3 supplementation in forty nine black youth,
evaluated the relation between 25(OH)D concentrations
and total body fat mass by dual-energy x-ray absorp-
tiometry. The experimental group compared with the con-
trols reached significantly higher 25(OH)D concentrations
at 16 wk (85.7±30.1 nmol/liter vs. 59.8±18.2 nmol/liter,
P<0.001, respectively) and partial correlation analyses indi-
cated that total body fat mass at baseline was significantly
and inversely associated with 25(OH)D concentrations in
response to the 2000 IU supplement (R = -0.46; P = 0.03).
Zhou et al [37] in a large-scale, placebo controlled,
double-blind, 4-year longitudinal clinical trial, investigated
the effect of calcium and vitamin D supplementation on
obesity in postmenopausal women, randomly assigned
into one of three groups: 1) supplemental calcium
(1400 mg/d or 1500 mg/d) plus vitamin D placebo (Ca-
only group); 2) supplemental calcium (1400 mg/d or
1500 mg/d) plus supplemental vitamin D3 (1100 IU/d)
(Ca +D group); or, 3) two placebos. No significant differ-
ence was observed for body mass index between groups,
but changes in trunk fat (for Ca-only and Ca + D groups
compared to the placebo group preserved lower trunk fat
2.4%, 1.4% vs. 5.4%, P = 0.015 at year 3) and trunk lean
(for Ca-only and Ca +D groups preserved more trunk lean
compared to the placebo group, -0.6%, -1.0% vs. -2.1%,
P = 0.004 at year 4), were significantly different between
groups. Major et al [38] conducted a randomized, double-
blind, placebo-controlled study to compare the effects of a
15 week weight-reducing program (-700 kcal/d) coupled
with a calcium plus vitamin D supplementation (600 mg
elemental calcium and 5 mg vitamin D, twice a day or pla-
cebo), on the body fat of sixty-three overweight or obese
women. The calcium+D supplementation did not induce
statistically significant increase in fat mass loss. However,
when analyses were limited to very low-calcium consu-
mers only (initial calcium intake ≤600 mg/d), significant
time × treatment interaction were observed in body
weight (P<0·009), BMI (P<0·008) and fat mass (P<0.02).Waist circumference decreased in both groups and there
were significant treatment effects (P = 0.03). Zittermann et
al [39] investigated the effect of vitamin D (83 μg/d) on
weight loss in overweight subjects with a mean 25(OH)D
concentration of 30 nmol/L in a double-blind manner for
12 months while participating in a weight-reduction pro-
gram. Their results showed that although weight loss was
not affected significantly by vitamin D supplementation,
waist circumference however decreased in both groups
and there were significant treatment effects (P = 0.022).
Body fat mass did not alter after the intervention.
It has been suggested that high levels of calcitrophic hor-
mones such as 1α,25,dihydroxyvitamin D and iPTH can
modulate intracellular Ca + 2 concentrations, so increasing
Ca + 2 flux to adiposities, which stimulate fatty acid syn-
thase enzyme, may increase lipogenesis and inhibit lipolysis
[25]. According to this hypothesis, 1α, 25dihydroxyvitamin
D is known as a key factor that provokes triglyceride accu-
mulation in adiposities [18] a finding not confirmed by
others [39]. Vitamin D insufficiency and secondary hyper-
parathyroidism lead to PTH related phospholipase C acti-
vation in adiposities, a process, which is followed by
increase in intracellular calcium [40,41]. Chronic increase
in [Ca + 2] may attenuate the ability of catecholamines in
activating of lipolysis by increasing the activity of Ca + 2
related cAMP phosphodiesterase [42]. Meanwhile, with in-
creasing of [Ca + 2], induction of fatty acid synthase is
strengthened, which facilitates de novo lipogenesis [43].
Thus hyperparathyroidism can affect weight gain [44,45].
The primary limitation of our study is that we could
not assess body composition by Dual X-Ray Absorp-
tiometry (DXA) as a gold standard method. However,
Bioelectrical Impedance Analysis is a validated and re-
liable method to assess body composition. A second
limitation is that Resting Metabolic Rate (RMR) was
not determined in subjects. Although our main goal
was to examine the effect of vitamin D3 supplementa-
tion on body composition. A third potential limitation
is not evaluating sun exposure, a confounding factor,
which can not be completely ruled out. However, the
subjects were requested not to use sunscreen during
the intervention.Conclusions
To summarize, based on result of the 12 week vitamin D3
supplementation, we concluded body fat mass decreased
in healthy overweight and obese women via increase in
serum 25(OH) D and decrease in iPTH concentrations.
Further investigation into whether vitamin D may play a
role in regulation of body composition is warranted.Competing interests
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